Alpine Global Management LLC Has $397,000 Holdings in Veru Inc. (NASDAQ:VERU)

Alpine Global Management LLC cut its position in Veru Inc. (NASDAQ:VERU) by 6.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 610,070 shares of the company’s stock after selling 39,930 shares during the period. Alpine Global Management LLC’s holdings in Veru were worth $397,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. NewEdge Advisors LLC raised its holdings in shares of Veru by 2,500.0% in the fourth quarter. NewEdge Advisors LLC now owns 130,000 shares of the company’s stock valued at $85,000 after buying an additional 125,000 shares during the last quarter. Barclays PLC increased its position in Veru by 11.8% in the 4th quarter. Barclays PLC now owns 206,515 shares of the company’s stock valued at $134,000 after acquiring an additional 21,738 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Veru by 23.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 406,755 shares of the company’s stock worth $265,000 after acquiring an additional 75,997 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Veru by 37.1% during the fourth quarter. Wells Fargo & Company MN now owns 75,512 shares of the company’s stock valued at $49,000 after purchasing an additional 20,430 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Veru by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,997,751 shares of the company’s stock valued at $1,950,000 after purchasing an additional 57,611 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors.

Veru Price Performance

Veru stock opened at $0.52 on Tuesday. Veru Inc. has a one year low of $0.45 and a one year high of $1.75. The company has a market cap of $76.54 million, a price-to-earnings ratio of -2.01 and a beta of -0.69. The firm has a 50-day moving average of $0.53 and a 200-day moving average of $0.67.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. As a group, sell-side analysts expect that Veru Inc. will post -0.22 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of Veru in a report on Thursday, January 2nd.

Insider Transactions at Veru

In other Veru news, Director Michael L. Rankowitz acquired 95,279 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was purchased at an average price of $0.55 per share, with a total value of $52,403.45. Following the acquisition, the director now directly owns 195,279 shares of the company’s stock, valued at approximately $107,403.45. This trade represents a 95.28 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 14.90% of the company’s stock.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.